Dexmedetomidine Use in Critically Ill Children with Acute Respiratory Failure

  • Mary Jo C. Grant
  • , James B. Schneider
  • , Lisa A. Asaro
  • , Brenda L. Dodson
  • , Brent A. Hall
  • , Shari L. Simone
  • , Allison S. Cowl
  • , Michele M. Munkwitz
  • , David Wypij
  • , Martha A.Q. Curley

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Care of critically ill children includes sedation but current therapies are suboptimal. To describe dexmedetomidine use in children supported on mechanical ventilation for acute respiratory failure. Design: Secondary analysis of data from the Randomized Evaluation of Sedation Titration for Respiratory Failure clinical trial. Setting: Thirty-one PICUs. Patients: Data from 2,449 children; 2 weeks to 17 years old. Interventions: Sedation practices were unrestrained in the usual care arm. Patients were categorized as receiving dexmedetomidine as a primary sedative, secondary sedative, periextubation agent, or never prescribed. Dexmedetomidine exposure and sedation and clinical profiles are described. Measurements and Main Results: Of 1,224 usual care patients, 596 (49%) received dexmedetomidine. Dexmedetomidine as a primary sedative patients (n = 138; 11%) were less critically ill (Pediatric Risk of Mortality III-12 score median, 6 [interquartile range, 3-11]) and when compared with all other cohorts, experienced more episodic agitation. In the intervention group, time in sedation target improved from 28% to 50% within 1 day of initiating dexmedetomidine as a primary sedative. Dexmedetomidine as a secondary sedative usual care patients (n = 280; 23%) included more children with severe pediatric acute respiratory distress syndrome or organ failure. Dexmedetomidine as a secondary sedative patients experienced more inadequate pain (22% vs 11%) and sedation (31% vs 16%) events. Dexmedetomidine as a periextubation agent patients (n = 178; 15%) were those known to not tolerate an awake, intubated state and experienced a shorter ventilator weaning process (2.1 vs 2.3 d). Conclusions: Our data support the use of dexmedetomidine as a primary agent in low criticality patients offering the benefit of rapid achievement of targeted sedation levels. Dexmedetomidine as a secondary agent does not appear to add benefit. The use of dexmedetomidine to facilitate extubation in children intolerant of an awake, intubated state may abbreviate ventilator weaning. These data support a broader armamentarium of pediatric critical care sedation.

Original languageEnglish (US)
Pages (from-to)1131-1141
Number of pages11
JournalPediatric Critical Care Medicine
Volume17
Issue number12
DOIs
StatePublished - Dec 1 2016

Keywords

  • agitation
  • endotracheal intubation
  • extubation
  • pediatric intensive care
  • withdrawal

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Critical Care and Intensive Care Medicine

Fingerprint

Dive into the research topics of 'Dexmedetomidine Use in Critically Ill Children with Acute Respiratory Failure'. Together they form a unique fingerprint.

Cite this